U.S. Physical Therapy, Inc.

Historical 13F Holders

Symbol
USPH
CUSIP
90337L108
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 90337L108 since 12/18/2024, newest first.

Filer % of Class Filed
Kayne Anderson Rudnick Investment Management, LLC 13G/A Amendment 12 5.6% 8/13/2026
Event 6/30/2026
Morgan Stanley 13G/A Amendment 3 3.9% 8/12/2026
Event 6/30/2026
Copeland Capital Management, LLC 13G/A Amendment 1 5.5% 8/4/2026
Event 6/30/2026
Copeland Capital Management, LLC 13G 5.5% 5/8/2026
Event 3/31/2026
Bahl & Gaynor Inc 13G 5.1% 5/8/2026
Event 1/15/2026
Vanguard Capital Management LLC 13G 5.1% 4/30/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 7 0% 3/27/2026
Event 3/13/2026
Kayne Anderson Rudnick Investment Management, LLC 13G/A Amendment 11
8.0%
Checked 5% or less
 2/13/2026
Event 12/31/2025
Copeland Capital Management, LLC 13G 5.2% 1/29/2026
Event 12/31/2025
Copeland Capital Management, LLC 13G 5.5%
Checked 5% or less
 10/15/2025
Event 9/30/2025
Kayne Anderson Rudnick Investment Management, LLC 13G/A Amendment 10
9.8% 8/13/2025
Event 6/30/2025
Copeland Capital Management, LLC 13G 5.9% 7/21/2025
Event 6/30/2025
BlackRock, Inc. 13G/A Amendment 4 14.2% 7/18/2025
Event 6/30/2025
Kayne Anderson Rudnick Investment Management, LLC 13G/A Amendment 9 6.2% 5/14/2025
Event 3/31/2025
Copeland Capital Management, LLC 13G 5.4% 4/24/2025
Event 3/31/2025
Kayne Anderson Rudnick Investment Management, LLC 13G/A Amendment 8
6.7%
Checked 5% or less
 2/13/2025
Event 12/31/2024
Morgan Stanley 13G/A Amendment 2
5.9%
Checked 5% or less
 2/5/2025
Event 12/31/2024
Copeland Capital Management, LLC 13G 5.6% 1/24/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 9 11.3 k $970 k
2026 Q2 221 17.3 M $1.13 B
2026 Q1 232 16.1 M $1.20 B
2025 Q4 238 16.1 M $1.26 B
2025 Q3 251 16.1 M $1.37 B
2025 Q2 245 15.8 M $1.23 B
2025 Q1 260 15.3 M $1.11 B
2024 Q4 260 15.6 M $1.38 B
2024 Q3 262 15.6 M $1.32 B
2024 Q2 250 16.4 M $1.52 B
2024 Q1 244 18.0 M $2.03 B
2023 Q4 218 16.7 M $1.55 B
2023 Q3 224 15.4 M $1.41 B
2023 Q2 221 15.3 M $1.86 B
2023 Q1 210 13.7 M $1.34 B
2022 Q4 209 13.9 M $1.13 B
2022 Q3 205 13.1 M $1.00 B
2022 Q2 212 13.5 M $1.47 B
2022 Q1 217 12.8 M $1.27 B
2021 Q4 221 12.8 M $1.22 B
2021 Q3 215 12.7 M $1.40 B
2021 Q2 228 12.7 M $1.47 B
2021 Q1 220 12.6 M $1.31 B
2020 Q4 217 13.2 M $1.59 B
2020 Q3 192 13.0 M $1.13 B
2020 Q2 193 13.5 M $1.10 B
2020 Q1 206 14.0 M $960 M
2019 Q4 221 13.1 M $1.50 B
2019 Q3 220 13.3 M $1.73 B
2019 Q2 222 13.3 M $1.64 B
2019 Q1 225 13.3 M $1.40 B
2018 Q4 203 13.2 M $1.35 B
2018 Q3 205 12.7 M $1.51 B
2018 Q2 189 12.5 M $1.20 B
2018 Q1 177 12.3 M $997 M
2017 Q4 168 11.9 M $862 M
2017 Q3 167 11.9 M $729 M
2017 Q2 176 11.9 M $722 M
2017 Q1 184 12.2 M $799 M
2016 Q4 176 12.5 M $885 M
2016 Q3 176 11.7 M $734 M
2016 Q2 168 12.3 M $749 M
2016 Q1 153 11.8 M $587 M
2015 Q4 145 12.3 M $660 M
2015 Q3 132 11.8 M $532 M
2015 Q2 133 11.6 M $633 M
2015 Q1 130 11.3 M $539 M
2014 Q4 128 11.2 M $472 M
2014 Q3 117 11.3 M $400 M
2014 Q2 110 11.2 M $383 M
2014 Q1 108 11.1 M $382 M